Genmab ADR (NASDAQ: GMAB) kicked off on Tuesday, up 0.68% from the previous trading day, before settling in for the closing price of $23.43. Over the past 52 weeks, GMAB has traded in a range of $23.24-$35.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 43.21% over the past five years. While this was happening, its average annual earnings per share was recorded 32.23%. With a float of $635.05 million, this company’s outstanding shares have now reached $653.30 million.
Let’s look at the performance matrix of the company that is accounted for 2204 employees. In terms of profitability, gross margin is 96.83%, operating margin of 31.65%, and the pretax margin is 39.39%.
Genmab ADR (GMAB) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Genmab ADR is 0.00%, while institutional ownership is 7.71%.
Genmab ADR (GMAB) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 32.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.10% during the next five years compared to 20.52% growth over the previous five years of trading.
Genmab ADR (NASDAQ: GMAB) Trading Performance Indicators
Take a look at Genmab ADR’s (GMAB) current performance indicators. Last quarter, stock had a quick ratio of 5.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.45. Likewise, its price to free cash flow for the trailing twelve months is 16.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.22, a number that is poised to hit 0.32 in the next quarter and is forecasted to reach 1.44 in one year’s time.
Technical Analysis of Genmab ADR (GMAB)
Genmab ADR (NASDAQ: GMAB) saw its 5-day average volume 0.73 million, a positive change from its year-to-date volume of 0.58 million. As of the previous 9 days, the stock’s Stochastic %D was 22.13%. Additionally, its Average True Range was 0.44.
During the past 100 days, Genmab ADR’s (GMAB) raw stochastic average was set at 5.13%, which indicates a significant decrease from 10.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.96% in the past 14 days, which was higher than the 26.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.36, while its 200-day Moving Average is $28.10. Nevertheless, the first resistance level for the watch stands at $23.69 in the near term. At $23.78, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.89. If the price goes on to break the first support level at $23.49, it is likely to go to the next support level at $23.38. The third support level lies at $23.29 if the price breaches the second support level.
Genmab ADR (NASDAQ: GMAB) Key Stats
The company with the Market Capitalisation of 14.98 billion has total of 661,299K Shares Outstanding. Its annual sales at the moment are 2,392 M in contrast with the sum of 631,910 K annual income. Company’s last quarter sales were recorded 779,510 K and last quarter income was 203,170 K.
